Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI112 in Moderate-to-Severe Plaque Psoriasis (Phase III, China)
CTR20223213Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of picankibart in plaque psoriasis, psoriatic arthritis (PsA), sponsored by InnoCare Pharma. Started Dec 2022; status: completed.
02
Drugs
picankibart
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20223213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223213.